This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer’s disease

Authors

Troussière, Anne-Cécile, Monaca Charley, Christelle, Salleron, Julia, Richard, Florence, Delbeuck, Xavier, Derambure, Philippe, Pasquier, Florence, Bombois, Stéphanie

Journal

Journal Of Neurology, Neurosurgery, And Psychiatry, Volume: 85, No.: 12, Pages.: 1405-1408

Year of Publication

2014

Abstract

Background: It is essential to detect and then treat factors that aggravate Alzheimer’s disease (AD). Here, we sought to determine whether or not continuous positive airway pressure (CPAP) therapy for sleep apnoea syndrome (SAS) slows the rate of cognitive decline in mild-to-moderate AD patients.; Methods: Between January 2003 and June 2011, we included consecutive, mild-to-moderate AD patients (a Mini Mental State Examination (MMSE) score at inclusion ≥15) with severe SAS as determined by video-polysomnography (an apnoea-hypopnoea index ≥30). In this single-blind, proof-of-concept trial, we analysed the mean decline in the annual MMSE score (the main outcome measure) according to whether or not the patients had received CPAP therapy. The decline was computed for each patient and for the first 3 years of follow-up.; Results: Of the 23 included patients, 14 underwent CPAP treatment. The CPAP and non-CPAP groups did not differ significantly in terms of their demographic characteristics or MMSE score at baseline. The median annual MMSE decline was significantly slower in the CPAP group (-0.7 (-1.7; +0.8)) than in the non-CPAP group (-2.2 (-3.3; -1.9); p=0.013).; Conclusions: In this pilot study, CPAP treatment of severe SAS in mild-to-moderate AD patients was associated with significantly slower cognitive decline over a three-year follow-up period. Our results emphasise the importance of detecting and treating SAS in this population.; Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Bibtex Citation

@article{Troussi_re_2014, doi = {10.1136/jnnp-2013-307544}, url = {http://dx.doi.org/10.1136/jnnp-2013-307544}, year = 2014, month = {may}, publisher = {{BMJ}}, volume = {85}, number = {12}, pages = {1405--1408}, author = {Anne-C{'{e}}cile Troussi{`{e}}re and Christelle Monaca Charley and Julia Salleron and Florence Richard and Xavier Delbeuck and Philippe Derambure and Florence Pasquier and St{'{e}}phanie Bombois}, title = {Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer{textquotesingle}s disease}, journal = {Journal of Neurology, Neurosurgery {&} Psychiatry} }

Keywords

aged, alzheimer disease, alzheimer’s disease, apnoea, cognition, complications, continuous positive airway pressure, csf, disease progression, female, for, humans, male, neuropsychological tests, polysomnography, sleep, sleep apnea syndromes, sleep apnoea, therapy, treatment

Countries of Study

France

Types of Dementia

Alzheimer’s Disease

Types of Study

Non randomised controlled trial

Type of Outcomes

Cognition, Prevention and/or management of co-morbidities

Type of Interventions

Treatment/prevention of co-morbidities or additional risks

Co-Morbidities

Other